Engineering T cells with chimeric antigen receptors (CARs) has demonstrated remarkable success in eradicating hematological malignancies. In this issue of Immunity, June and colleagues demonstrate the broad antitumor efficacy of a newly-designed CAR targeting the O-linked hypoglycosylated epitopes Tn and sialyl-Tn on cancer-associated MUC-1. Engineering T cells with chimeric antigen receptors (CARs) has demonstrated remarkable success in eradicating hematological malignancies. June and colleagues demonstrate the broad antitumor efficacy of a newly-designed CAR targeting the O-linked hypoglycosylated epitopes Tn and sialyl-Tn on cancer-associated MUC-1. © 2016 Elsevier Inc.
Documento: | Artículo |
Título: | Driving CARs into Sweet Roads: Targeting Glycosylated Antigens in Cancer |
Autor: | Blidner, A.G.; Mariño, K.V.; Rabinovich, G.A. |
Filiación: | Laboratorio de Inmunopatología, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Vuelta de Obligado 2490, Buenos Aires, C1428ADN, Argentina Laboratorio de Glicómica Funcional y Molecular, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Vuelta de Obligado 2490, Buenos Aires, C1428ADN, Argentina Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Intendente Güiraldes 2160, Buenos Aires, C1428EGA, Argentina |
Palabras clave: | antigen; artificial receptor; carbohydrate antigen; carcinoembryonic antigen; chimeric antigen receptor; cytotoxic T lymphocyte antigen 4; epidermal growth factor receptor 2; epitope; gamma interferon; ganglioside GD2; glycosylated antigen; glycosylated protein; interleukin 2; lentivirus vector; mesothelin; monoclonal antibody; mucin 1; programmed death 1 ligand 1; programmed death 1 receptor; single chain fragment variable antibody; theratope; Tn antigen; tumor marker; unclassified drug; acute lymphoblastic leukemia; antineoplastic activity; breast cancer; cancer immunization; cancer immunotherapy; cell therapy; clinical trial (topic); cytotoxicity; drug targeting; genetic engineering; hematologic malignancy; human; lymphatic system tumor; malignant transformation; neoplasm; nonhuman; priority journal; Short Survey; solid tumor; T cell leukemia; T lymphocyte; glycosylation; immunology; neoplasm; Glycosylation; Humans; Neoplasms; T-Lymphocytes |
Año: | 2016 |
Volumen: | 44 |
Número: | 6 |
Página de inicio: | 1248 |
Página de fin: | 1250 |
DOI: | http://dx.doi.org/10.1016/j.immuni.2016.06.010 |
Título revista: | Immunity |
Título revista abreviado: | Immunity |
ISSN: | 10747613 |
CODEN: | IUNIE |
CAS: | epidermal growth factor receptor 2, 137632-09-8; gamma interferon, 82115-62-6; ganglioside GD2, 65988-71-8; interleukin 2, 85898-30-2; mucin 1, 212255-06-6; single chain fragment variable antibody, 334577-34-3, 334577-38-7 |
Registro: | https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_10747613_v44_n6_p1248_Blidner |